|Videos|July 18, 2014
PD-1 Combinations Explored in RCC
Advertisement
Episodes in this series
For High-Definition, Click
Several clinical studies will continue to investigation PD-1 inhibition in renal cell carcinoma, explains Brian I. Rini, MD. A large phase I study showed modest activity with nivolumab as a single-agent, with questions regarding a maximum tolerated dose still lingering.
The next wave of research will focus on combination strategies, specifically looking at nivolumab with a TKI, such as sunitinib or pazopanib. The most intriguing combination involves nivolumab and ipilimumab. This approach has shown promising activity for patients with melanoma, Rini notes.
View the video, to hear the discussion.
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5